Asia Pacific Epilepsy Market Forecast to 2030 - Regional Analysis - by Type (Progressive Myoclonic Epilepsy, Reflex Epilepsy, Generalized Epilepsy, and Other), Route of Administration (Oral, Parenteral, and Others), Treatment Type (First Generation Drugs, Second Generation Drugs, and Third Generation Drugs), Age Group (Adult and Children), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others)

BMIRE00030724 | Pages: 146 | Pharmaceuticals | Sep 2024 | Type: Regional | Status: Published

The Asia Pacific epilepsy market was valued at US$ 2,200.92 million in 2022 and is expected to reach US$ 3,143.44 million by 2030; it is estimated to register a CAGR of 4.6% from 2022 to 2030.

Surge in Awareness Program Conducted by Organizations Boosts Asia Pacific Epilepsy Market

Growing awareness about epilepsy, its symptoms, and the importance of early diagnosis has led to a surge in patients seeking medical attention. Organizations such as the Epilepsy Foundation, Epilepsy Society, the American Epilepsy Society, and the Epilepsy Association of Central Florida play a crucial role in educating people about this disease. The involvement of these organizations has resulted in increased rates of diagnosis and a broader patient population requiring epilepsy treatment. Numerous awareness campaigns are conducted by organizations worldwide to spread awareness regarding the condition and available treatment. In 2023, on the Purple Day of Epilepsy, Aster Prime Hospitals in Hyderabad (India), in collaboration with the Walkers Association of Krishna Kant Park, held an awareness activity. One hundred fifty participants in total, including walkers and yoga practitioners, attended this session. Additionally, in order to improve the quality of life for Australians living with epilepsy, Epilepsy Action Australia offers a variety of tools and services aimed at raising awareness, educating, and equipping individuals with the necessary skills. Thus, such initiatives and awareness campaigns result in an increase in epilepsy diagnoses and treatments, offering lucrative growth opportunities to the market.

Asia Pacific Epilepsy Market Overview

The Asia Pacific epilepsy market is analyzed based on China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. According to the World Health Organization (WHO) report, epilepsy is more common in developing countries than in developed countries, accounting for a prevalence of 6.1% and 5.0%, respectively.

Asia Pacific Epilepsy Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Epilepsy Market Revenue and Forecast to 2030 (US$ Million)

Get more information on this report :

Asia Pacific Epilepsy Market Segmentation

The Asia Pacific epilepsy market is categorized into type, route of administration, treatment type, age group, distribution channel, and country.

Based on type, the Asia Pacific epilepsy market is categorized into progressive myoclonic epilepsy, reflex epilepsy, generalized epilepsy, and other. The generalized epilepsy segment held the largest market share in 2022.

In terms of route of administration, the Asia Pacific epilepsy market is categorized into oral, parenteral, and others. The oral segment held the largest market share in 2022.

By treatment type, the Asia Pacific epilepsy market is segmented into first generation drugs, second generation drugs, and third generation drugs. The third generation drugs segment held the largest market share in 2022.

Based on age group, the Asia Pacific epilepsy market is bifurcated into adult and children. The adult segment held a larger market share in 2022.

In terms of distribution channel, the Asia Pacific epilepsy market is categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest market share in 2022.

By country, the Asia Pacific epilepsy market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific epilepsy market share in 2022.

Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, and H. Lundbeck AS are some of the leading companies operating in the Asia Pacific epilepsy market.

TABLE OF CONTENTS

 

1. Introduction

1.1 The Insight Partners Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Asia Pacific Pipeline Studies for Epilepsy Therapy Approaches

4.1 Pipeline Studies for Epilepsy Therapy Approaches

4.1.1 Cell and Gene Therapy Approaches

4.1.2 Encapsulated cell bio delivery (ECB) system

4.1.3 Gene Therapy for Epilepsy Clinical Overview

4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy

4.1.3.1.1 Gene Supplementation - Overview

4.1.3.1.2 Gene Modulation - Overview

4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview

4.1.3.1.4 Neuropeptides - Overview

4.1.3.1.5 Engineered Channels - Overview

4.1.3.1.6 Endogenous Channels - Overview

4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy

4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy

4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy

4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy

4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview

4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches

4.1.3.6 Potassium Channels For Human Epileptic Phenotypes

4.1.3.7 Enzyme Inducing Antiepileptic Drugs

5. Asia Pacific Epilepsy Market - Key Market Dynamics

5.1 Market Drivers

5.1.1 Rising Prevalence of Epilepsy

5.1.2 Increasing Investments in Development of Epilepsy Therapies

5.2 Market Restraints

5.2.1 Recall of Products

5.3 Market Opportunities

5.3.1 Surge in Awareness Programs Conducted by Organizations

5.4 Future Trends

5.4.1 Gene Therapy as Promising Treatment Approach

5.5 Impact of Drivers and Restraints:

6. Epilepsy Market - Asia Pacific Analysis

6.1 Asia Pacific: Epilepsy Market

7. Asia Pacific Epilepsy Market Analysis - by Type

7.1 Overview

7.2 Progressive Myoclonic Epilepsy

7.2.1 Overview

7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

7.3 Reflex Epilepsy

7.3.1 Overview

7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

7.4 Generalized Epilepsy

7.4.1 Overview

7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

7.5 Other

7.5.1 Overview

7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Epilepsy Market Analysis - by Route of Administration

8.1 Overview

8.2 Oral

8.2.1 Overview

8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8.3 Parenteral

8.3.1 Overview

8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8.4 Others

8.4.1 Overview

8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Epilepsy Market Analysis - by Treatment Type

9.1 Overview

9.2 First Generation Drugs

9.2.1 Overview

9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9.3 Second Generation Drugs

9.3.1 Overview

9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9.4 Third Generation Drugs

9.4.1 Overview

9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Epilepsy Market Analysis - by Age Group

10.1 Overview

10.2 Adult

10.2.1 Overview

10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

10.3 Children

10.3.1 Overview

10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11. Asia Pacific Epilepsy Market Analysis - by Distribution Channel

11.1 Overview

11.2 Hospital Pharmacies

11.2.1 Overview

11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11.3 Retail Pharmacies

11.3.1 Overview

11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11.4 Others

11.4.1 Overview

11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12. Asia Pacific Epilepsy Market - Country Analysis

12.1 Asia Pacific Epilepsy Market Overview

12.1.1 Asia Pacific: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)

12.1.1.1 China: Epilepsy Market Overview

12.1.1.2 China: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12.1.1.2.1 China: Epilepsy Market Breakdown, by Type

12.1.1.2.2 China: Epilepsy Market Breakdown, by Route of Administration

12.1.1.2.3 China: Epilepsy Market Breakdown, by Treatment Type

12.1.1.2.4 China: Epilepsy Market Breakdown, by Age Group

12.1.1.2.5 China: Epilepsy Market Breakdown, by Distribution Channel

12.1.1.3 Japan: Epilepsy Market Overview

12.1.1.4 Japan: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12.1.1.4.1 Japan: Epilepsy Market Breakdown, by Type

12.1.1.4.2 Japan: Epilepsy Market Breakdown, by Route of Administration

12.1.1.4.3 Japan: Epilepsy Market Breakdown, by Treatment Type

12.1.1.4.4 Japan: Epilepsy Market Breakdown, by Age Group

12.1.1.4.5 Japan: Epilepsy Market Breakdown, by Distribution Channel

12.1.1.5 India: Epilepsy Market Overview

12.1.1.6 India: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12.1.1.6.1 India: Epilepsy Market Breakdown, by Type

12.1.1.6.2 India: Epilepsy Market Breakdown, by Route of Administration

12.1.1.6.3 India: Epilepsy Market Breakdown, by Treatment Type

12.1.1.6.4 India: Epilepsy Market Breakdown, by Age Group

12.1.1.6.5 India: Epilepsy Market Breakdown, by Distribution Channel

12.1.1.7 Australia: Epilepsy Market Overview

12.1.1.8 Australia: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12.1.1.8.1 Australia: Epilepsy Market Breakdown, by Type

12.1.1.8.2 Australia: Epilepsy Market Breakdown, by Route of Administration

12.1.1.8.3 Australia: Epilepsy Market Breakdown, by Treatment Type

12.1.1.8.4 Australia: Epilepsy Market Breakdown, by Age Group

12.1.1.8.5 Australia: Epilepsy Market Breakdown, by Distribution Channel

12.1.1.9 South Korea: Epilepsy Market Overview

12.1.1.10 South Korea: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12.1.1.10.1 South Korea: Epilepsy Market Breakdown, by Type

12.1.1.10.2 South Korea: Epilepsy Market Breakdown, by Route of Administration

12.1.1.10.3 South Korea: Epilepsy Market Breakdown, by Treatment Type

12.1.1.10.4 South Korea: Epilepsy Market Breakdown, by Age Group

12.1.1.10.5 South Korea: Epilepsy Market Breakdown, by Distribution Channel

12.1.1.11 Rest of Asia Pacific: Epilepsy Market Overview

12.1.1.12 Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12.1.1.12.1 Rest of Asia Pacific: Epilepsy Market Breakdown, by Type

12.1.1.12.2 Rest of Asia Pacific: Epilepsy Market Breakdown, by Route of Administration

12.1.1.12.3 Rest of Asia Pacific: Epilepsy Market Breakdown, by Treatment Type

12.1.1.12.4 Rest of Asia Pacific: Epilepsy Market Breakdown, by Age Group

12.1.1.12.5 Rest of Asia Pacific: Epilepsy Market Breakdown, by Distribution Channel

13. Industry Landscape

13.1 Overview

13.2 Growth Strategies in Epilepsy Market

13.3 Organic Growth Strategies

13.3.1 Overview

13.4 Inorganic Growth Strategies

13.4.1 Overview

14. Company Profiles

14.1 Abbott Laboratories

14.1.1 Key Facts

14.1.2 Business Description

14.1.3 Products and Services

14.1.4 Financial Overview

14.1.5 SWOT Analysis

14.1.6 Key Developments

14.2 Pfizer Inc

14.2.1 Key Facts

14.2.2 Business Description

14.2.3 Products and Services

14.2.4 Financial Overview

14.2.5 SWOT Analysis

14.2.6 Key Developments

14.3 Eisai Co Ltd

14.3.1 Key Facts

14.3.2 Business Description

14.3.3 Products and Services

14.3.4 Financial Overview

14.3.5 SWOT Analysis

14.3.6 Key Developments

14.4 UCB SA

14.4.1 Key Facts

14.4.2 Business Description

14.4.3 Products and Services

14.4.4 Financial Overview

14.4.5 SWOT Analysis

14.4.6 Key Developments

14.5 LivaNova Plc

14.5.1 Key Facts

14.5.2 Business Description

14.5.3 Products and Services

14.5.4 Financial Overview

14.5.5 SWOT Analysis

14.5.6 Key Developments

14.6 Novartis AG

14.6.1 Key Facts

14.6.2 Business Description

14.6.3 Products and Services

14.6.4 Financial Overview

14.6.5 SWOT Analysis

14.6.6 Key Developments

14.7 Medtronic Plc

14.7.1 Key Facts

14.7.2 Business Description

14.7.3 Products and Services

14.7.4 Financial Overview

14.7.5 SWOT Analysis

14.7.6 Key Developments

14.8 GSK Plc

14.8.1 Key Facts

14.8.2 Business Description

14.8.3 Products and Services

14.8.4 Financial Overview

14.8.5 SWOT Analysis

14.8.6 Key Developments

14.9 H. Lundbeck AS

14.9.1 Key Facts

14.9.2 Business Description

14.9.3 Products and Services

14.9.4 Financial Overview

14.9.5 SWOT Analysis

14.9.6 Key Developments

15. Appendix

15.1 About The Insight Partners

List of Tables

Table 1. Asia Pacific Epilepsy Market Segmentation

Table 2. Cell Therapy Approach - An Overview

Table 3. Gene Therapy Approach - An Overview

Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview

Table 5. Preclinically Tested Genetic Therapies for Epilepsy

Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview

Table 7. Viral Vectors Comparison with respect to Various Parameters

Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies

Table 9. Enzyme-Inducing Antiepileptic Drugs

Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Targets Types Overview

Table 11. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 12. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 13. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type

Table 14. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group

Table 15. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 16. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 17. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 18. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type

Table 19. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group

Table 20. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 21. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 22. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 23. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type

Table 24. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group

Table 25. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 26. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 27. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 28. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type

Table 29. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group

Table 30. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 31. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 32. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 33. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type

Table 34. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group

Table 35. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 36. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 37. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 38. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type

Table 39. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group

Table 40. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 41. Recent Organic Growth Strategies in Epilepsy Market

Table 42. Recent Inorganic Growth Strategies in the Epilepsy Market

List of Figures

Figure 1. Asia Pacific Epilepsy Market Segmentation, by Country

Figure 2. Epilepsy Market - Key Market Dynamics

Figure 3. Impact Analysis of Drivers and Restraints

Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030

Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)

Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)

Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)

Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)

Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)

Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 25. Asia Pacific: Epilepsy Market, by Key Country - Revenue (2022) (US$ Million)

Figure 26. Asia Pacific: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)

Figure 27. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)

Figure 28. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)

Figure 29. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)

Figure 30. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)

Figure 31. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)

Figure 32. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)

Figure 33. Growth Strategies in Epilepsy Market

 

  1. Abbott Laboratories
  2. Pfizer Inc
  3. Eisai Co Ltd
  4. UCB SA
  5. LivaNova Plc
  6. Novartis AG
  7. Medtronic Plc
  8. GSK Plc
  9. H. Lundbeck AS
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific epilepsy market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific epilepsy market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific epilepsy market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3550
$2840
Site License
$4550
$3640
Enterprise License
$5550
$4440